Unavailable
Unavailable
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/23/2024 | $4.00 | Buy | BTIG Research |
8-K - Spectral AI, Inc. (0001833498) (Filer)
10-Q - Spectral AI, Inc. (0001833498) (Filer)
8-K - Spectral AI, Inc. (0001833498) (Filer)
Second Quarter Revenue Totals $7.5 Million Total Enrollment Exceeds 85% for Burn Center Pivotal U.S. Clinical Trial Q2 2024 Overview Research & Development Revenue of $7.5 MillionCash Position of $6.9 MillionOn Track to Generate First Commercial Revenues in the U.K. Later this YearBurn Pivotal Study Nearing Completion Paving the Way for U.S. FDA Submission in Early 2025Announced Collaboration with PolyNovo Ltd. Providing Introduction to Australian MarketContinued Progress in Handheld Burn Wound Diagnostic TechnologyAdded to Russell Microcap® Index effective July 1, 2024 DALLAS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), a
DALLAS, July 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the second quarter ended June 30, 2024 on Monday, August 12, 2024 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day to discuss the results. Investors interested in participating in the live call can dial: 833-630-1956 - U.S.412-317-1837 - International A simultaneous webcast of the call may be accesse
Q1 Overview Research & Development Revenue of $6.3 MillionImproved Capital Structure Reflected in Cash of $10.2 MillionDeepView AI®-Burn Devices Deployed in UK; Expect Commercial Revenue in 2H 2024 Additional Regulatory Submissions in US and UK for DeepView™ System Expected in 2024 and 2025 DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2024 ("Q1 2024") and provided an update on its ongoing business activities. "During the
SC 13G/A - Spectral AI, Inc. (0001833498) (Subject)
SC 13D/A - Spectral AI, Inc. (0001833498) (Subject)
SC 13D/A - Spectral AI, Inc. (0001833498) (Subject)
Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced a 30% increase in its patent portfolio that strengthens and protects its proprietary, AI-driven DeepView System wound assessment platform. Total patents granted to the Company increased to 26 through July 8, 2024 from 20 at December 31, 2023, consisting of 12 U.S. and 14 international patents. These patents cover various aspects of the Company's DeepView System platform, including, but not limited to, tissue classification based on multi-spectral imaging, machine learning and he
Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has added three new U.S. Clinical Trial Sites for its 2024 Burn Pivotal Study: University Medical Center (UMC) Burn Center at Texas Tech University Health Sciences Center led by principal investigator Alan Pang, M.D., Tampa General Hospital Burn Center led by principal investigator Jared Troy, M.D., and University of South Alabama (USA) Health Emergency Department led by Andrew Bright, D.O.These new locations expand the total number of U.S. Clinical Trial Sites to 16, co
HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Spectral AI (NASDAQ:MDAI) with a Buy rating and announces Price Target of $3.5.
BTIG Research initiated coverage of Spectral AI with a rating of Buy and set a new price target of $4.00
DALLAS, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today provided an outline of its regulatory pathway strategy to enter the U.S. market with its flagship DeepView® System for burn indication ("DeepView AI®-Burn"). DeepView AI®-Burn, which received Breakthrough Device Designation from the U.S. Food and Drug Administration ("FDA") in 2018, is a predictive medical device that assesses the healing potential of burns by combining multi-spectral imaging with an AI-driven algorithm trained and tested aga
DALLAS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today provided an overview of a study conducted by the American Burn Association ("ABA") highlighting the physical and economic barriers to burn care access faced by rural and pediatric patients. The Company also discussed how its DeepView® System for burn indication can help broaden equity in access to burn treatment while optimizing healthcare resources. Each year, approximately 400,000 individuals in the United States receive medical treatment f
DALLAS, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has received a new award of over $850,000 from the Medical Technology Enterprise Consortium ("MTEC"). This award will support the ongoing development of DeepView SnapShot M®, Spectral AI's handheld predictive burn wound healing device targeted for use in battlefield assessment that is based on the Company's AI-driven DeepView™ System platform. The MTEC is a 501(c)(3) biomedical consortium collaborating with the U.S. Army Me
DALLAS, May 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective following the closing of US equity markets on Friday, June 28, 2024 according to a preliminary list of additions posted Friday, May 24, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, 2024 ranking them by total market capitalization. Members
DALLAS, May 15, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2024 Annual Meeting of Stockholders held on May 14, 2024 (the "AGM"). At the AGM, stockholders overwhelmingly approved each of the four proposals set forth by the Company. The voting results are detailed below. Six directors were elected to serve until the next Annual Meeting of Stockholders: Richard Cotton, Chairman of the Company's Board of DirectorsPeter M. Carlson, Chief Executive Officer of the
DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Jeremiah A. Sparks as Chief Commercialization Officer. Jeremiah has more than 20 years of medical device marketing experience, including global marketing and business strategy. Mr. Sparks will be responsible for both domestic and international product commercialization. "We are thrilled to have Jeremiah join the company as we move towards commercialization of DeepView," said Peter M. Carlson, CEO of Spectral AI.
4 - Spectral AI, Inc. (0001833498) (Issuer)
4 - Spectral AI, Inc. (0001833498) (Issuer)
4 - Spectral AI, Inc. (0001833498) (Issuer)
4 - Spectral AI, Inc. (0001833498) (Issuer)